U.S., Nov. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07241910) titled 'A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2061' on Nov. 17.
Brief Summary: This is a randomized, double-blind, placebo-controlled, single-ascending dose study in healthy subjects to evaluate the safety, tolerability, PK, and PD of SYH2061.
Study Start Date: Nov. 24
Study Type: INTERVENTIONAL
Condition:
Healthy Subjects
Intervention:
DRUG: SYH2061
subcutaneous injection
DRUG: Placebo
subcutaneous injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Disclaimer: Curated by HT Syndication....